MHLW Expedites the Reviews of Gilead’s Remdesivir to Treat Patients with COVID-19 in Japan

MHLW Expedites the Reviews of Gilead’s Remdesivir to Treat Patients with COVID-19 in Japan

Shots: Shots:

  • Japan will fast-track a review of Gilead’s remdesivir to approve it for COVID-19 patients, following the US FDA’s EUA for the therapy. If approved, Remdesivir would become Japan’s first recognized therapy for COVID-19
  • For remdesivir, the health ministry will apply a special approval system to shorten the screen-time for the therapy. In late Apr, the government reported that remdesivir needs to be introduced for emergency use and fast-track the procedures to greenlight domestic sales of the therapy, under the pharmaceuticals and medical devices law
  • Remdesivir was previously failed as an Ebola treatment and is being evaluated against COVID-19 due to its ability to disable the mechanism by which the viruses replicate itself. According to a study published by NEJM, the therapy is effective in ~70% patients with severe symptoms of COVID-19

Click here ­to­ read full press release/ article | Ref: The Japan Times  | Image: Star

Related News: Gilead’s Remdesivir Receives the US FDA’s Emergency Use Authorization for the Treatment of COVID-19